SG11202005926XA - SALT OF PYRAZOLO[1,5-a]PYRIMIDINE COMPOUND AND CRYSTALS THEREOF - Google Patents
SALT OF PYRAZOLO[1,5-a]PYRIMIDINE COMPOUND AND CRYSTALS THEREOFInfo
- Publication number
- SG11202005926XA SG11202005926XA SG11202005926XA SG11202005926XA SG11202005926XA SG 11202005926X A SG11202005926X A SG 11202005926XA SG 11202005926X A SG11202005926X A SG 11202005926XA SG 11202005926X A SG11202005926X A SG 11202005926XA SG 11202005926X A SG11202005926X A SG 11202005926XA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazolo
- crystals
- salt
- pyrimidine compound
- pyrimidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018031646 | 2018-02-26 | ||
| PCT/JP2019/006850 WO2019163956A1 (ja) | 2018-02-26 | 2019-02-22 | ピラゾロ［１，５－ａ］ピリミジン化合物の塩およびその結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005926XA true SG11202005926XA (en) | 2020-07-29 |
Family
ID=67687243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005926XA SG11202005926XA (en) | 2018-02-26 | 2019-02-22 | SALT OF PYRAZOLO[1,5-a]PYRIMIDINE COMPOUND AND CRYSTALS THEREOF |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11312720B2 (zh) |
| EP (1) | EP3760631B1 (zh) |
| JP (1) | JP7257376B2 (zh) |
| KR (1) | KR20200124655A (zh) |
| CN (1) | CN111655694B (zh) |
| AU (1) | AU2019224410A1 (zh) |
| BR (1) | BR112020015729A2 (zh) |
| CA (1) | CA3088718A1 (zh) |
| IL (1) | IL276160A (zh) |
| MX (1) | MX2020008110A (zh) |
| RU (1) | RU2020125450A (zh) |
| SG (1) | SG11202005926XA (zh) |
| TW (1) | TW201936607A (zh) |
| WO (1) | WO2019163956A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11141418B1 (en) * | 2018-06-22 | 2021-10-12 | The Board Of Regents, The University Of Texas System | Methods and compositions for KRAS inhibitors |
| WO2021106864A1 (en) * | 2019-11-25 | 2021-06-03 | Eisai R&D Management Co., Ltd. | Process for the preparation of producing pyrazolo[1,5-a] pyrimidine derivatives |
| CA3220630A1 (en) | 2021-06-02 | 2022-12-08 | Otsuka Pharmaceutical Co., Ltd. | Pyrazolo[1,5-a]pyrimidine compound for the treatment of dermal disorders |
| WO2023233033A1 (en) | 2022-06-03 | 2023-12-07 | Domain Therapeutics | Novel par-2 inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6833371B2 (en) * | 2001-11-01 | 2004-12-21 | Icagen, Inc. | Pyrazolopyrimidines |
| JP2003286171A (ja) | 2002-03-28 | 2003-10-07 | Sumitomo Pharmaceut Co Ltd | Ｐａｒ阻害剤 |
| JP2004170323A (ja) | 2002-11-22 | 2004-06-17 | Sumitomo Pharmaceut Co Ltd | 皮膚疾患治療剤のスクリーニング方法 |
| WO2005030773A1 (ja) | 2003-09-26 | 2005-04-07 | Dainippon Sumitomo Pharma Co., Ltd. | 新規ピラゾロピリミジン誘導体 |
| AU2011221075B2 (en) | 2010-02-26 | 2013-12-19 | Mitsubishi Tanabe Pharma Corporation | Pyrazolopyrimidine compounds and their use as PDE10 inhibitors |
| US9045485B2 (en) | 2010-12-16 | 2015-06-02 | Convergence Pharmaceuticals Limited | ASK 1 inhibiting pyrrolopyrimidine derivatives |
| GB201101517D0 (en) | 2011-01-28 | 2011-03-16 | Proximagen Ltd | Receptor antagonists |
| JP5531066B2 (ja) | 2011-08-24 | 2014-06-25 | 田辺三菱製薬株式会社 | ピラゾロピリミジン化合物及びｐｄｅ１０阻害剤としてのその使用 |
| EP3049418A1 (en) * | 2013-09-25 | 2016-08-03 | Vertex Pharmaceuticals Incorporated | Imidazopyridazines useful as inhibitors of the par-2 signaling pathway |
| TWI732031B (zh) * | 2016-08-31 | 2021-07-01 | 日商衛材R&D企管股份有限公司 | 吡唑并[1, 5-a]嘧啶化合物 |
-
2019
- 2019-02-22 SG SG11202005926XA patent/SG11202005926XA/en unknown
- 2019-02-22 TW TW108105948A patent/TW201936607A/zh unknown
- 2019-02-22 WO PCT/JP2019/006850 patent/WO2019163956A1/ja active Application Filing
- 2019-02-22 CA CA3088718A patent/CA3088718A1/en active Pending
- 2019-02-22 BR BR112020015729-5A patent/BR112020015729A2/pt not_active Application Discontinuation
- 2019-02-22 MX MX2020008110A patent/MX2020008110A/es unknown
- 2019-02-22 CN CN201980010733.4A patent/CN111655694B/zh active Active
- 2019-02-22 US US16/965,067 patent/US11312720B2/en active Active
- 2019-02-22 JP JP2020501065A patent/JP7257376B2/ja active Active
- 2019-02-22 RU RU2020125450A patent/RU2020125450A/ru unknown
- 2019-02-22 AU AU2019224410A patent/AU2019224410A1/en not_active Abandoned
- 2019-02-22 KR KR1020207022677A patent/KR20200124655A/ko not_active Application Discontinuation
- 2019-02-22 EP EP19757272.0A patent/EP3760631B1/en active Active
-
2020
- 2020-07-20 IL IL276160A patent/IL276160A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN111655694B (zh) | 2023-03-28 |
| WO2019163956A1 (ja) | 2019-08-29 |
| EP3760631A1 (en) | 2021-01-06 |
| RU2020125450A (ru) | 2022-03-28 |
| IL276160A (en) | 2020-09-30 |
| JP7257376B2 (ja) | 2023-04-13 |
| US20210107907A1 (en) | 2021-04-15 |
| CN111655694A (zh) | 2020-09-11 |
| EP3760631A4 (en) | 2021-10-20 |
| EP3760631B1 (en) | 2023-11-08 |
| US11312720B2 (en) | 2022-04-26 |
| BR112020015729A2 (pt) | 2020-12-08 |
| TW201936607A (zh) | 2019-09-16 |
| JPWO2019163956A1 (ja) | 2021-02-04 |
| RU2020125450A3 (zh) | 2022-03-28 |
| KR20200124655A (ko) | 2020-11-03 |
| MX2020008110A (es) | 2020-11-06 |
| AU2019224410A1 (en) | 2020-07-09 |
| CA3088718A1 (en) | 2019-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276160A (en) | A salt of the compound pyrazolo[5,1-]pyrimidine and its crystals | |
| IL266170A (en) | A process for the preparation of pyrazolo[1,5-a]pyrimidines and their salts | |
| HK1257146A1 (zh) | 新型的吡唑並[3，4-d]嘧啶化合物或其鹽 | |
| IL281127A (en) | Pyrazolo[3,4-B]pyridine compounds as inhibitors of TAM and MET kinases | |
| IL288997A (en) | Salt forms of Bampedoic acid and methods of using them | |
| EP3268000A4 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
| PH12020550143A1 (en) | Salts of pyrrolotriazine derivatives useful as tam inhibitors | |
| IL282446A (en) | Pyrrolo[2,3-D]pyrimidine tosylate salt, their crystalline form and production process and intermediates between them | |
| EP3744723A4 (en) | SUBSTITUTED MACROCYCLIC PYRAZOLO [1,5-A] PYRIMIDINE COMPOUND | |
| IL262673A (en) | A pyrazolo[5,1-a]pyrimidine compound | |
| RS65243B1 (sr) | Jedinjenje [1,2,4]triazolo[1,5-a]piridina kao inhibitor jak i njegova primena | |
| EP3730492A4 (en) | COMPOUND PYRAZOLO [1,5-A] PYRIMIDINE SUBSTITUTE, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USE | |
| EP3856743A4 (en) | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | |
| SG11202107528PA (en) | Pyrimidine compound or salt thereof | |
| PL3766884T3 (pl) | Postać krystaliczna i rodzaj soli związku triazolopirymidynowego oraz sposób jej wytwarzania | |
| HUE055530T2 (hu) | 7H-pirrolo[2,3-D]pirimidin vegyület kristály formája és só formája, és ezek elkészítési eljárása | |
| EP3805229C0 (en) | SALT OF A CONDENSATED RING PYRIMIDINE COMPOUND, ITS CRYSTAL FORM AND METHOD FOR THE PRODUCTION THEREOF AND THEREOF USE | |
| EP3758696A4 (en) | [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AND USE OF THESE IN THE STABILIZATION OF MICROTUBULES | |
| EP3750905A4 (en) | SALT OF HETEROCYCLIC COMPOUND SUBSTITUTED BY PYRANOSIS, PROCESS FOR PREPARATION AND USE | |
| EP3845537A4 (en) | PYRAZOLO[3,4-D]PYRIMIDINE CRYSTAL | |
| EP3330271A4 (en) | PYRROLO [2,3-D] PYRIMIDINE COMPOUND OR SALT THEREOF | |
| EP3727379A4 (en) | PYRAZOLO [1,5-A] PYRIDINE DERIVATIVE SALTS AND THEIR USE | |
| IL253427B (en) | The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose | |
| EP3903788A4 (en) | PYRAZOLO[1,5-A] PYRIMIDINE MACROCYCLIC COMPOUND | |
| EP3845231A4 (en) | THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT |